Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Adjuvanted Influenza Vaccines: Version II
share announcement

Adjuvanted Influenza Vaccines: Version II

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Influenza Virus Vaccines".

Deadline for manuscript submissions: closed (5 June 2023) | Viewed by 4148

Special Issue Editors

Dr. Eduardo Gomez-Casado

E-Mail Website
Guest Editor
Department of Biotechnology, INIA-CSIC, 28040 Madrid, Spain
Interests: viral immunology; innate immunity; adaptive immunity; adjuvants; vaccines; immune pathways; fish immunology; rhabdovirus; virus-host interaction; RNA virus; DNA virus
Special Issues, Collections and Topics in MDPI journals
Dr. Dheeraj Soni

E-Mail Website
Guest Editor
Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
Interests: vaccines; adjuvants; inflammation; formulation; small molecules; antigen presenting cells; macrophages; dendritic cells, Immunology; pharmacology; vascular biology; molecular biology; cellular signaling pathways; kinases; phosphatase; TLR; MAPK; vaccine safety; influenza; SARS-CoV2; tissue culture
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Despite current influenza vaccines being immunogenic, the evolution of the influenza virus can reduce their efficacy, so influenza remains a major threat to public health. One approach to improving influenza vaccines is to include adjuvants. An immunologic adjuvant is defined as a substance that acts to accelerate, prolong, or enhance antigen-specific immune responses when used in combination with specific vaccine antigens. Adjuvants are particularly beneficial for influenza vaccines administered during a pandemic, when a rapid response is required or for use in patients with impaired immune responses. To date, six adjuvants have been used in licensed human vaccines: Alum, MF59, AS03, AF03, virosomes, and heat-labile enterotoxin (LT).

This Issue will address the potential of novel adjuvant strategies to modulate innate and adaptive immune responses to facilitate the development of improved prophylactic or therapeutic vaccines. Submission of original articles and systematic reviews is welcome. Manuscripts will follow standard journal peer-review practices and those accepted for publication will appear in the Special Issue, “Adjuvanted Influenza Vaccines: Version II”. We welcome and look forward to receiving your contributions.

Dr. Eduardo Gomez-Casado
Dr. Dheeraj Soni 
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • adjuvant
  • vaccine
  • particulate adjuvant
  • innate immunity
  • adaptive immunity
  • nanoparticle
  • AS03
  • Alum
  • MF59
  • antibody
  • formulation

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

16 pages, 2172 KiB  
Article
Unconjugated Multi-Epitope Peptides Adjuvanted with ALFQ Induce Durable and Broadly Reactive Antibodies to Human and Avian Influenza Viruses
by Nimisha Rikhi, Clara J. Sei, Mangala Rao, Richard F. Schuman, Kellie A. Kroscher, Gary R. Matyas, Kevin Muema, Camille Lange, Aba Assiaw-Dufu, Elizabeth Hussin, Ousman Jobe, Carl R. Alving and Gerald W. Fischer
Vaccines 2023, 11(9), 1468; https://doi.org/10.3390/vaccines11091468 - 08 Sep 2023
Viewed by 1632
Abstract
An unconjugated composite peptide vaccine targeting multiple conserved influenza epitopes from hemagglutinin, neuraminidase, and matrix protein and formulated with a safe and highly potent adjuvant, Army Liposome formulation (ALFQ), generated broad and durable immune responses in outbred mice. The antibodies recognized specific epitopes [...] Read more.
An unconjugated composite peptide vaccine targeting multiple conserved influenza epitopes from hemagglutinin, neuraminidase, and matrix protein and formulated with a safe and highly potent adjuvant, Army Liposome formulation (ALFQ), generated broad and durable immune responses in outbred mice. The antibodies recognized specific epitopes in influenza peptides and several human, avian, and swine influenza viruses. Comparable antibody responses to influenza viruses were observed with intramuscular and intradermal routes of vaccine administration. The peptide vaccine induced cross-reactive antibodies that recognized influenza virus subtypes A/H1N1, A/H3N2, A/H5N1, B/Victoria, and B/Yamagata. In addition, immune sera neutralized seasonal and pandemic influenza strains (Group 1 and Group 2). This composite multi-epitope peptide vaccine, formulated with ALFQ and administered via intramuscular and intradermal routes, provides a high-performance supra-seasonal vaccine that would be cost-effective and easily scalable, thus moving us closer to a viable strategy for a universal influenza vaccine and pandemic preparedness. Full article
(This article belongs to the Special Issue Adjuvanted Influenza Vaccines: Version II)
►▼ Show Figures

Figure 1

9 pages, 1197 KiB  
Article
Intranasal Treatment of Ferrets with Inert Bacterial Spores Reduces Disease Caused by a Challenging H7N9 Avian Influenza Virus
by Joe James, Stephanie M. Meyer, Huynh A. Hong, Chau Dang, Ho T. Y. Linh, William Ferreira, Paidamoyo M. Katsande, Linh Vo, Daniel Hynes, William Love, Ashley C. Banyard and Simon M. Cutting
Vaccines 2022, 10(9), 1559; https://doi.org/10.3390/vaccines10091559 - 19 Sep 2022
Cited by 3 | Viewed by 2124
Abstract
Background: Influenza is a respiratory infection that continues to present a major threat to human health, with ~500,000 deaths/year. Continued circulation of epidemic subtypes in humans and animals potentially increases the risk of future pandemics. Vaccination has failed to halt the evolution of [...] Read more.
Background: Influenza is a respiratory infection that continues to present a major threat to human health, with ~500,000 deaths/year. Continued circulation of epidemic subtypes in humans and animals potentially increases the risk of future pandemics. Vaccination has failed to halt the evolution of this virus and next-generation prophylactic approaches are under development. Naked, “heat inactivated”, or inert bacterial spores have been shown to protect against influenza in murine models. Methods: Ferrets were administered intranasal doses of inert bacterial spores (DSM 32444K) every 7 days for 4 weeks. Seven days after the last dose, the animals were challenged with avian H7N9 influenza A virus. Clinical signs of infection and viral shedding were monitored. Results: Clinical symptoms of infection were significantly reduced in animals dosed with DSM 32444K. The temporal kinetics of viral shedding was reduced but not prevented. Conclusion: Taken together, nasal dosing using heat-stable spores could provide a useful approach for influenza prophylaxis in both humans and animals. Full article
(This article belongs to the Special Issue Adjuvanted Influenza Vaccines: Version II)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop